Bluebird Bio Inc. (NASDAQ:BLUE)’s share price dropped 2% on Thursday . The company traded as low as $45.27 and last traded at $45.59, with a volume of 396,613 shares traded. The stock had previously closed at $46.52.

A number of equities analysts recently commented on BLUE shares. Piper Jaffray Cos. reissued a “buy” rating and set a $117.00 price target on shares of Bluebird Bio in a research note on Saturday, March 19th. BTIG Research reissued a “buy” rating and set a $72.00 price target on shares of Bluebird Bio in a research note on Sunday, April 3rd. Zacks Investment Research raised Bluebird Bio from a “sell” rating to a “hold” rating in a research note on Tuesday, April 5th. Leerink Swann reissued an “outperform” rating and set a $67.00 price target on shares of Bluebird Bio in a research note on Tuesday, April 5th. Finally, Vetr lowered Bluebird Bio from a “strong-buy” rating to a “buy” rating and set a $55.90 price target for the company. in a research note on Wednesday, April 6th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $96.09.

The company’s market cap is $1.69 billion. The stock’s 50 day moving average is $44.02 and its 200 day moving average is $46.07.

Bluebird Bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, May 4th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.23) by $0.29. The firm had revenue of $1.50 million for the quarter, compared to analyst estimates of $4.50 million. The business’s revenue for the quarter was down 76.2% on a year-over-year basis. During the same period last year, the business earned ($0.76) EPS. Equities analysts forecast that Bluebird Bio Inc. will post ($5.90) earnings per share for the current fiscal year.

In related news, insider David Davidson sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $38.73, for a total transaction of $38,730.00. Following the sale, the insider now owns 10,600 shares in the company, valued at $410,538. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Philip D. Gregory sold 2,931 shares of the firm’s stock in a transaction that occurred on Thursday, June 16th. The stock was sold at an average price of $39.52, for a total transaction of $115,833.12. Following the sale, the insider now owns 30,069 shares in the company, valued at approximately $1,188,326.88. The disclosure for this sale can be found here.

A number of hedge funds have recently made changes to their positions in BLUE. Jennison Associates LLC raised its stake in shares of Bluebird Bio by 171.3% in the fourth quarter. Jennison Associates LLC now owns 864,314 shares of the company’s stock worth $55,506,000 after buying an additional 545,727 shares during the period. Wells Fargo & Company MN raised its position in shares of Bluebird Bio by 53.4% in the fourth quarter. Wells Fargo & Company MN now owns 474,832 shares of the company’s stock worth $30,492,000 after buying an additional 165,303 shares during the period. Marshall Wace LLP raised its position in shares of Bluebird Bio by 374.8% in the fourth quarter. Marshall Wace LLP now owns 168,427 shares of the company’s stock worth $10,816,000 after buying an additional 132,956 shares during the period. Baillie Gifford & Co. raised its position in shares of Bluebird Bio by 2.1% in the fourth quarter. Baillie Gifford & Co. now owns 4,883,321 shares of the company’s stock worth $313,607,000 after buying an additional 99,617 shares during the period. Finally, State of Tennessee Treasury Department raised its position in shares of Bluebird Bio by 45.4% in the fourth quarter. State of Tennessee Treasury Department now owns 191,963 shares of the company’s stock worth $12,328,000 after buying an additional 59,952 shares during the period.

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.